Symptomatic Remission Status in Patients with Schizophrenia Treated with Paliperidone Palmitate (1-month and 3-month formulations)

被引：0
|
作者：
Savitz, Adam [1 ]
Xu, Haiyan [1 ]
Gopal, Srihari [1 ]
Nuamah, Isaac [1 ]
Hough, David [1 ]
Mathews, Maju [1 ]
机构：
[1] Johnson & Johnson Pharmaceut R&D, Neurosci, Titusville, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2016年 / 79卷 / 09期
关键词：
Paliperidone palmitate 1-monthly; Paliperidone palmitate 3-monthly; schizophrenia; symptomatic remission; functional remission;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
1035
引用
收藏
页码：354S / 354S
页数：1
相关论文
共 50 条
  • [1] Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)
    Savitz, A.
    Xu, H.
    Gopal, S.
    Nuamah, I.
    Hough, D.
    Hargarter, L.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S546 - S547
  • [2] Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
    Nash, Abigail, I
    Turkoz, Ibrahim
    Savitz, Adam J.
    Mathews, Maju
    Kim, Edward
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 731 - 737
  • [3] Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations
    Russu, Alberto
    Savitz, Adam
    Mathews, Maju
    Gopal, Srihari
    Feng, Yu
    Samtani, Mahesh N.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 567 - 574
  • [4] Effect of two long-acting treatments, the paliperidone palmitate 1-month and 3-month formulations on caregiver burden in European patients with schizophrenia
    Hargarter, L.
    Gopal, S.
    Xu, H.
    McQuarrie, K.
    Savitz, A.
    Nuamah, I.
    Woodruff, K.
    Mathews, M.
    [J]. EUROPEAN PSYCHIATRY, 2017, 41 : S198 - S198
  • [5] Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
    Turkoz, Ibrahim
    Wong, Joshua
    Chee, Benjamin
    Siddiqui, Uzma
    Knight, R. Karl
    Richarz, Ute
    Correll, Christoph U.
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [6] COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
    Mathews, Maju
    Gopal, Srihari
    Singh, Arun
    Gogate, Jagadish
    Kim, Edward
    Pungor, Katalin
    [J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S311 - S311
  • [7] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE 3-MONTH VERSUS 1-MONTH FOR THE TREATMENT OF SCHIZOPHRENIA IN THE UNITED STATES
    Asgharian, A.
    Khushalani, A. S.
    Kremenova, L.
    Karki, S.
    Khan, S.
    Akat, M.
    Magruder, A.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2019, 22 : S227 - S227
  • [8] Paliperidone Palmitate 3-month Versus 1-month Formulation In Patients With Schizophrenia: A Randomized, Double-blind, Noninferiority Study
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    Fleischhacker, Wolfgang W.
    [J]. BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 354S - 354S
  • [9] Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia
    Savitz, A.
    Xu, H.
    Gopal, S.
    Nuamah, I.
    Ravenstijn, P.
    Hough, D.
    Hargarter, L.
    Fleischhacker, W. W.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S548 - S549
  • [10] Efficacy and Safety of Paliperidone Palmitate (3-Month versus 1-Month formulation) in European and Non-European Patients with Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Hough, David
    Hargartar, Ludger
    Fleischhacker, Wolfgang
    [J]. BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S211 - S211
12345